Get started
GSK plc Sponsored ADRGSK plc Sponsored ADRGSK plc Sponsored ADR

GSK plc Sponsored ADR

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Chart


Full chart

Key facts today


On December 9, 2025, GSK plc acquired 12,474,733 shares in its buyback program, raising total treasury shares to 237,939,577, or 5.84% of voting rights.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.77 T‬ MXN
Dividend yield (indicated)
3.43%
Price to earnings Ratio (TTM)
13.23
Basic EPS (TTM)
65.17 MXN
Net income (FY)
‪68.60 B‬ MXN
Revenue (FY)
‪835.91 B‬ MXN
Shares float
‪2.02 B‬
Beta (1Y)
0.31

Employees


Employees (FY)
‪68.63 K‬
Change (1Y)
‪−1.58 K‬ −2.25%
Revenue / Employee (1Y)
‪12.18 M‬ MXN
Net income / Employee (1Y)
‪999.61 K‬ MXN

About GSK plc


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Emma N. Walmsley
Website
gsk.com
Headquarters
London
ISIN
US37733W2044
FIGI
BBG00JX0NSM0
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Check out other big names from the same industry as GSK/N.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


17RI
GlaxoSmithKline Capital Plc 4.25% 18-DEC-2045
Yield to maturity
5.61%
Maturity date
Dec 18, 2045
83GI
GlaxoSmithKline Capital Plc 5.25% 10-APR-2042
Yield to maturity
5.58%
Maturity date
Apr 10, 2042
71ZC
GlaxoSmithKline Capital Plc 6.375% 09-MAR-2039
Yield to maturity
5.48%
Maturity date
Mar 9, 2039
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.31%
Maturity date
Mar 18, 2043
XS217060907
GlaxoSmithKline Capital Plc 1.625% 12-MAY-2035
Yield to maturity
5.09%
Maturity date
May 12, 2035
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
4.99%
Maturity date
May 15, 2038
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035
Yield to maturity
4.72%
Maturity date
Apr 15, 2035
72WI
GlaxoSmithKline Capital, Inc. 5.375% 15-APR-2034
Yield to maturity
4.67%
Maturity date
Apr 15, 2034
AG99
GlaxoSmithKline Capital Plc 5.25% 19-DEC-2033
Yield to maturity
4.58%
Maturity date
Dec 19, 2033
GSK6023695
GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030
Yield to maturity
4.14%
Maturity date
Apr 15, 2030
US377373AH8
GlaxoSmithKline Capital Plc 3.375% 01-JUN-2029
Yield to maturity
4.14%
Maturity date
Jun 1, 2029

See all GSK/N bonds 

ETFs


PPH
VanEck Pharmaceutical ETF
Weight
4.85%
Market value
‪57.03 M‬
USD
AVDE
Avantis International Equity ETF
Weight
0.40%
Market value
‪44.08 M‬
USD
FVD
First Trust Value Line Dividend Index Fund
Weight
0.43%
Market value
‪36.32 M‬
USD
FENI
Fidelity Enhanced International ETF
Weight
0.62%
Market value
‪34.24 M‬
USD
FTHI
Fidelity Tactical High Income Fund Trust Units
Weight
0.40%
Market value
‪25.48 M‬
USD
RODM
Hartford Multifactor Developed Markets (ex-US) ETF
Weight
1.15%
Market value
‪14.81 M‬
USD
DFAX
Dimensional World ex U.S. Core Equity 2 ETF
Weight
0.11%
Market value
‪11.02 M‬
USD
A
AQEC
AQE Core ETF
Weight
1.75%
Market value
‪10.49 M‬
USD
AVIV
Avantis International Large Cap Value ETF
Weight
0.98%
Market value
‪9.37 M‬
USD
BINV
Brandes International ETF
Weight
2.63%
Market value
‪8.66 M‬
USD
FFLC
Fidelity Fundamental Large Cap Core ETF
Weight
0.90%
Market value
‪8.41 M‬
USD

Explore more ETFs 

Sparks


Curated watchlists where GSK/N is featured.

See all sparks 

Frequently Asked Questions


The current price of GSK/N is 865.71 MXN — it has increased by 2.59% in the past 24 hours. Watch GSK plc Sponsored ADR stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange GSK plc Sponsored ADR stocks are traded under the ticker GSK/N.
We've gathered analysts' opinions on GSK plc Sponsored ADR future price: according to them, GSK/N price has a max estimate of 952.56 MXN and a min estimate of 824.33 MXN. Watch GSK/N chart and read a more detailed GSK plc Sponsored ADR stock forecast: see what analysts think of GSK plc Sponsored ADR and suggest that you do with its stocks.
GSK/N stock is 2.55% volatile and has beta coefficient of 0.31. Track GSK plc Sponsored ADR stock price on the chart and check out the list of the most volatile stocks — is GSK plc Sponsored ADR there?
Today GSK plc Sponsored ADR has the market capitalization of ‪1.79 T‬, it has decreased by −0.02% over the last week.
Yes, you can track GSK plc Sponsored ADR financials in yearly and quarterly reports right on TradingView.
GSK plc Sponsored ADR is going to release the next earnings report on Feb 4, 2026. Keep track of upcoming events with our Earnings Calendar.
GSK/N earnings for the last quarter are 26.70 MXN per share, whereas the estimation was 23.05 MXN resulting in a 15.86% surprise. The estimated earnings for the next quarter are 11.60 MXN per share. See more details about GSK plc Sponsored ADR earnings.
GSK plc Sponsored ADR revenue for the last quarter amounts to ‪207.47 B‬ MXN, despite the estimated figure of ‪202.29 B‬ MXN. In the next quarter, revenue is expected to reach ‪204.41 B‬ MXN.
GSK/N net income for the last quarter is ‪49.76 B‬ MXN, while the quarter before that showed ‪36.16 B‬ MXN of net income which accounts for 37.62% change. Track more GSK plc Sponsored ADR financial stats to get the full picture.
Yes, GSK/N dividends are paid quarterly. The last dividend per share was 7.50 MXN. As of today, Dividend Yield (TTM)% is 3.42%. Tracking GSK plc Sponsored ADR dividends might help you take more informed decisions.
GSK plc Sponsored ADR dividend yield was 4.53% in 2024, and payout ratio reached 94.89%. The year before the numbers were 3.87% and 47.48% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 9, 2025, the company has ‪68.63 K‬ employees. See our rating of the largest employees — is GSK plc Sponsored ADR on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GSK plc Sponsored ADR EBITDA is ‪266.64 B‬ MXN, and current EBITDA margin is 26.18%. See more stats in GSK plc Sponsored ADR financial statements.
Like other stocks, GSK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GSK plc Sponsored ADR stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GSK plc Sponsored ADR technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GSK plc Sponsored ADR stock shows the buy signal. See more of GSK plc Sponsored ADR technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.